Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17385951 | 0.86 | IDO1 (0.41) | IDO1HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL25367856 | 0.84 | IDO1 (0.42) | IDO1HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL14645765 | 0.80 | HSD17B10 (0.45) | HTR1ASLC6A4HSD17B10 | |
| SCHEMBL7551792 | 0.80 | ADRA1A (0.48) | IDO1HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL6752997 | 0.79 | IDO1 (0.58) | IDO1ADRA1ATAAR1HTR2AHSD17B10 | |
| SCHEMBL10026840 | 0.79 | IDO1 (0.41) | IDO1ADRA1ATAAR1HTR2AHSD17B10 | |
| SCHEMBL1058869 | 0.79 | HTR2A (0.44) | IDO1HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL2001551 | 0.79 | HSD17B10 (0.44) | IDO1HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL7352155 | 0.78 | HSD17B10 (0.48) | HSD17B10 | |
| SCHEMBL12775763 | 0.78 | CHRM2 (0.48) | ADRA1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009129365-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | CTSF, CTSZ, CTSG | IDO1 3467/4885HTR1A 4011/4885SLC6A4 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.